BioTime Inc. (BTX)

1.45
0.01 1.00
AMEX : Health Technology
Prev Close 1.46
Open 1.45
Day Low/High 1.43 / 1.48
52 Wk Low/High 0.66 / 2.90
Volume 342.34K
Avg Volume 1.04M
Exchange AMEX
Shares Outstanding 149.36M
Market Cap 233.00M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioTime Announces Closing Of Acquisition Of Asterias Biotherapeutics Creating Leading Cell Therapy Company

BioTime Announces Closing Of Acquisition Of Asterias Biotherapeutics Creating Leading Cell Therapy Company

BioTime, Inc. (NYSE American and TASE: BTX), today announced the closing of its previously reported acquisition of Asterias Biotherapeutics, Inc.

BioTime To Report Fourth Quarter And Full Year 2018 Financial Results On March 14th, 2019

BioTime To Report Fourth Quarter And Full Year 2018 Financial Results On March 14th, 2019

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its fourth quarter and full year 2018 financial and operating results on Thursday, March 14 th, 2019,...

BioTime To Present At The 14Th Annual Scientific Meeting Of The Association For Ocular Pharmacology And Therapeutics (AOPT 2019) On March 10, 2019

BioTime To Present At The 14Th Annual Scientific Meeting Of The Association For Ocular Pharmacology And Therapeutics (AOPT 2019) On March 10, 2019

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that Francois Binette, PhD, Senior Vice President and Global Head of Product Development at BioTime, Inc.

AgeX Therapeutics Publishes Data In Peer-Reviewed Journal To Advance Potential Cell Therapy AgeX-BAT1 For Type II Diabetes And Obesity

AgeX Therapeutics Publishes Data In Peer-Reviewed Journal To Advance Potential Cell Therapy AgeX-BAT1 For Type II Diabetes And Obesity

AgeX Therapeutics, Inc. (NYSE American: AGE) announced today the publication of data relating to its cell therapy product candidate AgeX-BAT1 for Type II diabetes and obesity in the peer-reviewed scientific journal Stem Cell Research & Therapy.

BioTime To Present At 2019 Biotech Showcase Investor Conference On January 7, 2019

BioTime To Present At 2019 Biotech Showcase Investor Conference On January 7, 2019

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M.

AgeX Therapeutics To Present At Biotech Showcase 2019

AgeX Therapeutics To Present At Biotech Showcase 2019

AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, today announced that it will present at  Biotech Showcase, to be held January 7-9, 2019 in San...

BioTime Announces Publication Of Positive Preclinical Results Utilizing Proprietary HyStem® Platform In Ischemic Stroke

BioTime Announces Publication Of Positive Preclinical Results Utilizing Proprietary HyStem® Platform In Ischemic Stroke

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the publication of positive preclinical results which demonstrate that targeted intracerebral delivery of brain-derived...

BioTime To Present At The LD Micro 11th Annual Main Event Investor Conference On December 5th, 2018

BioTime To Present At The LD Micro 11th Annual Main Event Investor Conference On December 5th, 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M.

AgeX Therapeutics, Inc. To Present Keynote Address At Advanced Stem Cell & Regenerative Medicine 2018 Conference

AgeX Therapeutics, Inc. To Present Keynote Address At Advanced Stem Cell & Regenerative Medicine 2018 Conference

AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced that its Founder and CEO Michael D.

AgeX Therapeutics, Inc. Shares Commence Trading On The NYSE American

AgeX Therapeutics, Inc. Shares Commence Trading On The NYSE American

AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced today that its common stock is now trading on the NYSE American exchange under the...

BioTime Announces Distribution Of AgeX Therapeutics Shares

BioTime Announces Distribution Of AgeX Therapeutics Shares

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that the registration statement on Form 10, including the information statement relating to the distribution that was...

BioTime And Asterias Biotherapeutics Enter Into Definitive Merger Agreement To Create Leading Cell Therapy Company

BioTime And Asterias Biotherapeutics Enter Into Definitive Merger Agreement To Create Leading Cell Therapy Company

BioTime, Inc. (NYSE American and TASE: BTX), and Asterias Biotherapeutics, Inc.

BioTime Reports Third Quarter 2018 Financial Results And Provides Business Update

BioTime Reports Third Quarter 2018 Financial Results And Provides Business Update

BioTime, Inc. (NYSE American:BTX), a clinical-stage biotechnology company focused on degenerative diseases, reported financial and operating results for the third quarter ended September 30, 2018.

BioTime Announces Update To Third Quarter 2018 Financial Results Conference Call

BioTime Announces Update To Third Quarter 2018 Financial Results Conference Call

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has changed the time of its previously announced conference call to discuss its third quarter 2018 financial and...

BioTime Receives Second Installment Payment Of $10.8 Million From Juvenescence Ltd.

BioTime Receives Second Installment Payment Of $10.8 Million From Juvenescence Ltd.

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has received the second installment payment of $10.

BioTime To Report Third Quarter 2018 Financial Results On November 8th, 2018

BioTime To Report Third Quarter 2018 Financial Results On November 8th, 2018

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its third quarter 2018 financial and operating results on Thursday, November 8 th, 2018, following...

BioTime Presents New OpRegen® Data At American Academy Of Ophthalmology Annual Meeting

BioTime Presents New OpRegen® Data At American Academy Of Ophthalmology Annual Meeting

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced positive additional results from an ongoing Phase I/IIa study of its lead product candidate, OpRegen ®, a retinal pigment...

BioTime Announces November 16, 2018 Record Date And November 28, 2018 Distribution Date For The Distribution Of Age-X Therapeutics Shares

BioTime Announces November 16, 2018 Record Date And November 28, 2018 Distribution Date For The Distribution Of Age-X Therapeutics Shares

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors has set the record date for and distribution date for the distribution of AgeX Therapeutics ("AgeX")...

BioTime To Present New OpRegen® Data At American Academy Of Ophthalmology Annual Meeting On October 28th

BioTime To Present New OpRegen® Data At American Academy Of Ophthalmology Annual Meeting On October 28th

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that updated results from a Phase I/IIa study of its lead product candidate, OpRegen ®, a retinal pigment epithelium cell...

BioTime To Present At The Upcoming Ladenburg Thalmann And MicroCap Conferences

BioTime To Present At The Upcoming Ladenburg Thalmann And MicroCap Conferences

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will present at the upcoming MicroCap and Ladenburg Thalmann conferences.

BioTime To Participate On Industry Perspectives Roundtable At NEI Audacious Goals In Regenerative Medicine Workshop: Pathways For Retinal Cell Replacement Therapies

BioTime To Participate On Industry Perspectives Roundtable At NEI Audacious Goals In Regenerative Medicine Workshop: Pathways For Retinal Cell Replacement Therapies

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Francois Binette, Senior Vice President and BioTime's Head of Global Development, will participate in a panel discussion at...

BioTime Warrants To Expire On October 1, 2018

BioTime Warrants To Expire On October 1, 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, is advising the holders of its publicly traded warrants (NYSE American: BTX.

BioTime Implements New Leadership Structure; Appoints Brian Culley As Chief Executive Officer

BioTime Implements New Leadership Structure; Appoints Brian Culley As Chief Executive Officer

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that the Board of Directors has implemented a new leadership structure under which Brian Culley has been appointed as the...

BioTime Updates Timeline For Distribution Of AgeX Shares To BioTime Shareholders

BioTime Updates Timeline For Distribution Of AgeX Shares To BioTime Shareholders

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors intends to set a new record date for the distribution of AgeX Therapeutics, Inc.

BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence

BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has closed the previously announced transaction with Juvenescence Limited, a global leader in developing therapeutics...

BioTime's CEO Adi Mohanty And CFO Russell Skibsted To Participate In Upcoming Panel And Conferences

BioTime's CEO Adi Mohanty And CFO Russell Skibsted To Participate In Upcoming Panel And Conferences

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer will participate in a panel discussion at the Annual B.

AgeX Therapeutics Acquires Technology To Regulate Immune Tolerance

AgeX Therapeutics Acquires Technology To Regulate Immune Tolerance

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc.

BioTime To Present Data At The Military Health System Research Symposium

BioTime To Present Data At The Military Health System Research Symposium

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will be presenting a poster at the Military Health System Research Symposium (MHSRS) from August 20-23, 2018 in Kissimmee,...

TheStreet Quant Rating: D (Sell)